The Westchester Biotech Project runs several Roundtable programs. Each of these meets 3-4 times per year and communicates online in between. This July our Roundtable for Researchers gathered regional opinion leaders to begin exploring ways to enhance appreciation of the significant breakthroughs. And, we were able to announce Westchester Biotech France!
This month the Westchester Biotech Project (WBP) convened its Roundtable: Building the Westchester Biotech Cluster, hosted by George Oros and Loren Zeitler at the Westchester County Industrial Development Agency (IDA), one of our many participants.
In attendance were Fareri Associates, Contrafect, Sapience Therapeutics, Skanska, Perkin Elmer, Albert Einstein College of Medicine, Taro Pharmaceuticals, and JLL. Additional WBP Founding Community Partners were represented by Chris Palermo from Bleakley Platt Schmidt and Keith Safian for the Westchester County Association.
Gary Keller, CEO of Xomix, Ltd. introduced the elements of a healthy biotech cluster, emphasizing the importance of a vibrant scientific community as the key source of innovation. “Each biotech hub is a unique ecosystem,” he says. “The Westchester Biotech Project (WBP) is taking the right first steps by establishing connections and support for the endeavor.“
Open discussion focused on challenges in hiring strong candidates. While the region enjoys a strikingly high level of education, opportunities for building a career in the sciences are in the early stages. That said, many of the other required resources are moving forward: adaptive facilities, biotech companies, support services companies, and financing. New and reconfigurable industrial parks and incubator spaces are helping to connect to global innovation resources for collaboration and soft landing.
Numerous initiatives are in the works, including the WBP’s Young Investigators and the Innovation in Research Symposium on October 26, 2017 at New York Medical College.
“According to the 2017 JLL life Sciences Outlook Report, Westchester Ranks as the #12 biotech cluster in the country”, says Michael Welling, partner at Meridian Risk Management and co-chair of the WBP. “It’s a great place to start”.